CTLA4 and neoplasm: The PD1/CTLA‐4 BsAb significantly inhibited tumor growth more effectively than the combination of aPD1 and aCTLA‐4 in MC38‐bearing mice, with tumor suppression rates of 96.8% and 77.3%, respectively.